The latest price target for Corcept Therapeutics (NASDAQ:CORT) was reported by Canaccord Genuity on January 30, 2025. The analyst firm set a price target for $130.00 expecting CORT to rise to within 12 months (a possible 91.18% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Corcept Therapeutics (NASDAQ:CORT) was provided by Canaccord Genuity, and Corcept Therapeutics maintained their buy rating.

The last upgrade for Corcept Therapeutics Inc happened on November 6, 2023 when Truist Securities raised their price target to $38. Truist Securities previously had a hold for Corcept Therapeutics Inc.

The last downgrade for Corcept Therapeutics Inc happened on February 15, 2023 when Jefferies changed their price target from $35 to $22 for Corcept Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corcept Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corcept Therapeutics was filed on January 30, 2025 so you should expect the next rating to be made available sometime around January 30, 2026.

While ratings are subjective and will change, the latest Corcept Therapeutics (CORT) rating was a maintained with a price target of $78.00 to $130.00. The current price Corcept Therapeutics (CORT) is trading at is $68.00, which is out of the analyst’s predicted range.